Myung In Pharmaceutical LTD. (KRX:317450)

Market Cap	830.74B
Revenue (ttm)	287.25B +6.6%
Net Income	81.44B +18.6%
EPS	6,718.00 +9.6%
Shares Out	14.60M
PE Ratio	8.47
Forward PE	n/a
Dividend	1,500.00 (2.84%)
Ex-Dividend Date	Dec 29, 2025

Volume	25,196
Average Volume	25,602
Open	57,400
Previous Close	56,300
Day's Range	56,300 - 57,700
52-Week Range	52,000 - 134,500
Beta	n/a
RSI	48.50
Earnings Date	Apr 14, 2026

About KRX:317450

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 335
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 317450

Financial Performance

In 2025, KRX:317450's revenue was 287.25 billion, an increase of 6.61% compared to the previous year's 269.43 billion. Earnings were 81.44 billion, an increase of 18.59%.